CIO Office

Global Markets Weekly Kickstart

Healthcare's Enduring Strength

31 August 2026

01 CIO Insights

The Debasement Trade in Disguise

02 Market Recap

Tech Rebound and Financial Strength Support U.S. Equities

Treasury Buybacks and Market Concerns Drive Gains in Gold and Bitcoin

03 What's Trending

NVIDIA Earnings Impress as Revenue Diversifies

04 In Focus

Diversify AI Exposure Through Multi-Strategy Investing

The Strategic Playbook Series: Healthcare Sector Resilience?

05 Strategic Viewpoint

Selective AI Opportunities Amid Rising Yields and Sector Rotation

06 Product Spotlight

Selection of Equities, Bonds, Funds/ETFs

CIO Insights

The Debasement Trade in Disguise

► **Rising Japanese Yields and Carry-Trade Unwinding Risk**

Higher Japanese inflation and a weaker yen are forcing Bank of Japan policy normalization, which elevates domestic yields and narrows the 30-year yield spread with the US to under 1.0 percentage point. Because Japan holds $1,116.7 billion in US Treasuries, this narrowing yield gap makes yen-funded foreign assets less attractive, threatening a global bond price sell-off and competitive selling as yen carry trades unwind.

► **Macroeconomic Pressures on Fixed Income and the US Dollar**

Rising long-term yields increase discount rates, compressing valuation multiples for long-duration equities, elevating corporate borrowing costs for capital-intensive sectors like AI, and eroding confidence in the US dollar. To protect portfolios against fiscal deficit concerns and long-end duration weakness, investors are advised to target the protected 2–5 year fixed income duration segment and hedge US asset exposure via long Yen forwards.

► **Alternative Asset Strategies (Gold and Bitcoin)**

Declining trust in US Treasuries and potential dollar weakness position gold and Bitcoin as attractive alternatives. Gold is regaining its safe-haven status—supported by resumed central bank buying in China—with peak performance expected in 1Q27 as high 2026 base effects lower inflation metrics and reopen room for rate cuts. Meanwhile, Bitcoin benefits from dollar depreciation and early investor positioning ahead of its scheduled spring 2028 halving event, though it remains a risk asset rather than a true crisis hedge.

China's Trade Surplus Is Not Being Invested in US Treasuries
Where Can China's Reserves Be Invested? Gold Is an Obvious Answer



Source: Bloomberg, KGI

Market Recap

Tech Rebound and Financial Strength Support U.S. Equities

- U.S. equities advanced, supported by stronger tech stocks and resilient financials. Semiconductor weakness, Canadian auto tariff threats, and rising long-term yields did not prevent major indices from posting weekly gains.
- NVIDIA rallied on strong revenue guidance, lifting U.S. technology stocks. Salesforce surged after raising its full-year revenue and earnings outlook and launching features integrated with Anthropic's Claude model, while CrowdStrike also gained following stronger guidance and solid second-quarter results.
- U.S. labor market data continued to indicate limited layoff pressure, with both initial and continuing jobless claims declining. Meanwhile, the goods trade deficit widened in July as exports fell and imports rose, supported by stronger capital goods imports.
- July headline and core PCE inflation remained at 3.7% and 3.3% YoY, respectively, offering little reason for markets to materially adjust expectations for Fed policy.

Regional Index Performance (%)



U.S. Sector Index Performance (%)



Source: Bloomberg

Market Recap

Treasury Buybacks and Market Concerns Drive Gains in Gold and Bitcoin

- The bond market was initially pressured this week by elevated long-term U.S. Treasury yields, as well as concerns over fiscal supply and term premium. Pressure on the long end eased temporarily after the U.S. Treasury increased the size of its long-term Treasury buyback program.
- U.S. high-yield bonds and emerging market bonds posted positive returns. Over the past three months, Asian investment-grade bonds, global and Asian high-yield bonds, and emerging market local-currency bonds have delivered relatively strong returns.
- The U.S. Treasury increased its monthly long-term Treasury buyback size from USD 2 billion to USD 4 billion. Coupled with persistent market concerns over U.S. debt, this supported the performance of gold and Bitcoin.
- Corporate credit supply was another key focus this week. U.S. investment-grade bond issuance exceeded USD 135 billion in August, with the tech. sector accounting for approximately USD 37 billion. Issuance is expected to increase further to USD 210-220 billion in September, while full-year net supply is projected at around USD 900 billion. Year-to-date, mega-cap cloud companies have increased bond issuance by approximately USD 145 billion.

Performance of Bonds (%)



Performance of Commodities and Currencies (%)



Source: Bloomberg

KGI

What's Trending

NVIDIA Earnings and Outlook Impress as Revenue Sources Continue to Diversify

- NVIDIA reported FY2Q27 revenue of USD 96.2 billion, up 18% QoQ and 106% YoY, exceeding the consensus estimate of USD 92.4 billion. Non-GAAP EPS came in at USD 2.22, ahead of market expectations. Data Center revenue reached USD 89.0 billion, supported by strong Blackwell demand, while ACIE revenue increased 25% QoQ.
- The key theme is that AI infrastructure is expanding beyond large CSPs to AI labs, sovereign AI, enterprises, and edge computing. KGI estimates non-large CSP customers could eventually account for about half of data center revenue, supporting a more diversified revenue base. Meanwhile, cloud industry backlog has exceeded USD 2 trillion, and the top five CSPs are expected to spend USD 1.3 trillion in capex by 2027, underpinning multi-year demand for GPUs, systems, networking, and software.
- Near-term catalysts include Rubin shipments and the production ramp of the Vera CPU. Improved supply of HBM, advanced packaging, and racks could provide upside to shipments and revenue. Current valuation assumptions include sustained AI capex, partial pass-through of memory costs, and gross margin recovery to 72-73% after reaching 71-72% in FY27 Q4.

Revenue Growth Remains Resilient





Customer Diversification Remains a Key Market Focus



Source: Bloomberg

What's Trending

Diversifying AI Exposure Through Multi-Strategy Investing

- The S&P 500 is market-cap weighted, with the top 25 constituents now accounting for over 50% of the index, resulting in concentration risk that exceeds dot-com era levels. We believe this risk can be mitigated through diversification strategies.
- Value Strategy: The largest U.S. companies are primarily growth stocks with relatively high valuations. Value stocks typically have lower P/B and P/E ratios and operate more mature businesses. Within the Russell 1000 Index, value stocks have historically shown lower upside capture, downside capture, and beta than growth stocks, indicating lower market sensitivity and volatility. This could provide greater downside resilience during periods of uncertainty.
- Covered Call Strategy: This strategy sacrifices part of the upside potential in exchange for option premium income. It may be attractive when the market lacks strong upside catalysts but does not warrant a bearish view. In addition, covered call strategies typically offer higher yield than the underlying equities, making them appealing for income-focused investors. Option premium income may also increase during periods of higher market volatility.

Top 25 S&P 500 Constituents Account for Over 50% of the Index



Covered Call Strategy - Trading Upside Potential for Income



Value Stocks Trade at Lower Valuations

Russell 1000 (USD B)

	Value	Core	Growth
P/B	3.5	5.3	13.5
Dividend Yield	1.6%	1.1%	0.5%
P/E	22.1	25.8	31.7
5-Year EPS Growth Rate	11.6%	15.1%	20.4%
Number of Constituents	869	1,022	367
Avg. Market Capitalization	796.8	1,408.7	2,112.9
Median Market Capitalization	16.0	17.2	26.6
Largest Constituent Market Capitalization	4,531.0	4,878.2	4,878.2

Value Stocks Outperform



Source: Bloomberg

In Focus

The Strategic Playbook Series: Unlocking the Healthcare Investment Opportunity Behind a 10% Share of Global GDP

1. **Healthcare Is a Major Component of Global GDP**

According to the WHO and OECD, global healthcare spending exceeds USD 10-12 trillion annually, accounting for approximately 9.5%-10% of global GDP.

- U.S.: 17%-18% of GDP
- OECD Average: 9.3% of GDP
- EU Average: 10.0% of GDP

2. **Growth and Defensive Characteristics**

The global healthcare market has delivered a long-term CAGR of 5.8%-9.0%, consistently outpacing global GDP growth of 2.5%-3.5%, highlighting its structural growth and defensive qualities.

3. **Structural Growth Drivers**

- Aging Population: Rapid growth in the 65+ population
- Chronic Diseases: Rising prevalence of diabetes, cardiovascular disease, cancer, and obesity
- Innovation: Breakthroughs such as GLP-1 therapies
- Emerging Markets: Increasing demand for quality healthcare from a growing middle class

Six Healthcare Subsectors

Subsector	TAM (US$)
1. Life Sciences Tools & Diagnostics Supplies research consumables, gene sequencing instruments, laboratory equipment, and in vitro diagnostics.	~$220B
2. Pharma & Biotech Develops, manufactures, and markets prescription drugs, biologics, vaccines, and novel therapies such as GLP-1 and ADCs.	~$1.8T
3. Medical Devices & MedTech Designs and manufactures diagnostic equipment, surgical robots, implants, and medical consumables.	~$600B
4. Healthcare IT & Digital Health Provides electronic health records, AI-assisted diagnostics, telehealth platforms, and hospital information systems.	~$400B
5. Healthcare Services & Providers Delivers clinical care, hospital services, dialysis, and long-term care.	~$9.5T
6. Health Insurance / Payers) Offers health insurance, managed care plans, and claims administration services.	~$3.8T

Diversifying Crowded AI Trades

S&P 500 Sector Return Correlations (3-Year, Weekly)

Lower Correlation with Crowded Sectors	Healthcare
Info. Tech.	0.19
Consumer Discretionary	0.26
Communication Services	0.21
Financials	0.49
Real Estate	0.54
Industrials	0.50
Energy	0.16
Materials	0.57
Consumer Staples	0.45
Utilities	0.32



Source: Bloomberg, KGI

The Strategic Playbook Series: Healthcare Sector Resilience?

- The healthcare sector is primarily driven by structural factors and is less sensitive to economic cycles. Unlike AI and technology, its key catalysts are FDA approvals and clinical data, rather than semiconductor cycles or enterprise cloud spending.
- Pharma and biotech account for over 60% of the global healthcare index. Key catalysts include clinical data, regulatory approvals, and patents, while the main structural risk is the patent cliff. Loss of exclusivity, trial failures, or approval delays can materially impact individual companies. Given the sector's diverse growth drivers and risks, stock-specific risk remains significant. Over the past 20 years, an annually rebalanced equal-weight portfolio delivered 18.4% annualized volatility, below most constituents (16.8%-43.5%), highlighting the benefits of diversification.
- Healthcare is positioned as a defensive and diversified sector, rather than one focused on maximizing growth. The industry's leadership has also remained relatively stable. In the U.S. healthcare sector index, seven of the top ten companies in 2006 remain among the top ten today, reflecting the durability of established industry leaders.

Source: Bloomberg, KGI

Portfolio Diversification Reduces Single-Stock Risk in Pharmaceuticals

2006/08/25 - 2026/08/21 (20-Year, Weekly Data)

		CAGR	Annualized Volatility
Portfolio		11.8%	18.4%
LLY	Eli Lilly	16.9%	26.5%
JNJ	Johnson & Johnson	7.4%	16.8%
RHHBY	Roche Holding	4.8%	23.1%
NVS	Novartis	6.3%	20.1%
MRK	Merck & Co.	6.9%	24.2%
AZN	AstraZeneca	5.0%	26.1%
NVO	Novo Nordisk	13.7%	30.2%
PFE	Pfizer	0.4%	23.0%
VRTX	Vertex Pharmaceuticals	14.7%	43.5%
REGN	Regeneron Pharmaceuticals	22.4%	41.1%

20-Year Weekly Return Correlations

	LLY	JNJ	RHHBY	NVS	MRK	AZN	NVO	PFE	VRTX
JNJ	0.48								
RHHBY	0.44	0.47							
NVS	0.49	0.55	0.64						
MRK	0.48	0.53	0.44	0.52					
AZN	0.42	0.44	0.53	0.59	0.45				
NVO	0.41	0.32	0.41	0.44	0.35	0.37			
PFE	0.45	0.53	0.46	0.53	0.53	0.44	0.33		
VRTX	0.32	0.28	0.28	0.32	0.26	0.29	0.22	0.27	
REGN	0.33	0.30	0.29	0.33	0.34	0.30	0.30	0.34	0.36

Large Pharma's Mature Business Models Reduce Cyclical Sensitivity

Top 10 Constituents of the S&P 500 Health Care Index in 2006	Years Ranked in the Top 10
Still in the Top 10 Today	
Johnson & Johnson - Pharmaceuticals	20
Pfizer- Pharmaceuticals	19
Merck & Co. - Pharmaceuticals	20
Amgen - Biotechnology	15
UnitedHealth - Healthcare Services & Providers	18
Abbott Laboratories - Healthcare Equip. & Supplies	16
Eli Lilly - Pharmaceuticals	13
No Longer in the Top 10 Today	
Wyeth – Pharmaceuticals	3
Medtronic - Healthcare Equip. & Supplies	13
Bristol-Myers Squibb – Pharmaceuticals	15

S&P 500 Worst Years Over the Past 20 Years



Strategic Viewpoint

Selective AI Opportunities Amid Rising Yields and Sector Rotation

Asset Type	Market View	Preferred Assets
Equities	◆ Rising sovereign debt and higher interest rates raise the risk of equity valuation adjustments, while heavy AI-related capex has increased focus on future profitability and monetization. Defensive sectors such as health care and utilities may help reduce volatility. At the same time, strong earnings and guidance from major tech companies support the long-term outlook for technology and AI semiconductors, with pullbacks offering opportunities to build positions while maintaining diversified exposure. ◆ European and Japanese equities remain attractive diversification opportunities. Higher rates continue to support banks, with European and Japanese financials backed by solid fundamentals. Japanese semiconductor stocks remain suitable for gradual accumulation, while European defense stocks continue to offer investment potential.	**Strategy:** Near-term sector rotation; constructive on AI-related themes, including technology and semiconductors, over the medium to long term. Complement AI exposure with cyclical sectors **Regions**: Japanese Banks, Japanese Semi., European Financials, European Defense
Bonds	◆ U.S. 30-year Treasury yields remain elevated, suggesting caution toward long-duration bonds. KGI expects the 10-year Treasury yield to trade within a 4.5%-5.0% range through year-end. Investors may consider locking in yields through short- to intermediate-duration bonds when rates rise. Preference remains for high-quality credits with stable cash flow and repayment capacity, particularly in the financials, technology, communication services, and utilities sectors. ◆ Non-U.S. currency bonds, such as euro- or Australian dollar-denominated investment-grade bonds, may also help diversify single-currency risk.	**Types:** Intermediate-duration, high-quality bonds in financials, technology, communication services, and utilities **Satellite :** Non-U.S. currency bonds for diversification
Forex	◆ U.S. inflation continues to ease, while oil prices remain elevated. The U.S. dollar is expected to trade within a range, though its strength has moderated. ◆ U.S.-Japan joint intervention has supported the yen, while the BoJ has signaled a more hawkish stance, increasing the likelihood of a September rate hike and supporting further yen appreciation.	**USD:** Range-bound at elevated levels **JPY:** Stabilizing and recovering against the U.S. dollar
Commodity	◆ Geopolitical conflicts in the Middle East and the Russia-Ukraine war continue to constrain global energy supply. Combined with peak summer fuel demand and declining oil inventories, energy markets are expected to remain undersupplied this year. ◆ U.S. fiscal pressures and ongoing de-dollarization remain key long-term structural themes. Continued central bank purchases should provide medium- to long-term support for gold.	**Oil**: Elevated prices amid recurring Middle East tensions **Gold**: Range trading

Product Spotlight | HK Equities

The Underlying Engine of Global Healthcare

► **Upstream Foundations of Biopharma R&D and Precision Diagnostics**

Life science tools and diagnostics sit at the very top of the global healthcare value chain, with a market size of about USD 220 billion, serving as the foundational pillar of the entire medical system. The sector supplies high-throughput NGS sequencers, mass spectrometers, bioprocess consumables, and IVD reagents. These are core facilities for pharma and CRO/CDMO partners in target screening, drug development, and large-scale production, while also enabling hospitals and diagnostic centers in early screening, companion diagnostics, and precision medicine—providing essential technology support for the USD 10 trillion global healthcare spend.

► **Empowering Precision Medicine and Efficiency Gains**

This subsector drives structural upgrades in modern healthcare through innovation. On the R&D side, high-resolution mass spectrometry and AI data tools accelerate target discovery and reduce early-stage attrition. On the clinical side, advanced IVD and CDx shift the system from traditional "symptom-based treatment" toward precision, personalized therapies.

► **High-Margin Recurring Revenue and Patent Cliff Immunity**

Life science tools and diagnostics enjoy a resilient business model. Once equipment is installed in pharma labs or diagnostic centers, it locks in recurring purchases of reagents and consumables with operating margins of 20–28%, generating sticky cash flows. Unlike traditional pharma, which faces high clinical failure risk (Phase I–III cumulative success rate only 8–10%) and the patent cliff, tool and diagnostic firms are insulated from single-drug outcomes and patent expirations. Their risks mainly stem from client capex cycles and biotech financing conditions—sales may fluctuate when pharma budgets tighten or funding slows, but overall the sector combines defensive attributes with capital-market sensitivity.

CRDMO Workflow



Source: WuXi AppTec Official Website

WuXi AppTec (2359 HK)

Closing Price	HK $199	Target Price	HK $219

A global leading CRDMO enterprise delivering integrated, end-to-end new drug R&D and manufacturing services across chemistry, testing, and biology. The company is committed to lowering development barriers and accelerating the time-to-market for innovative therapies.

GLP-1 Demand Fuels TIDES, Becoming Explosive Growth Engine

Benefiting from strong global demand for GLP-1 weight-loss and metabolic drugs, 1H26 TIDES revenue reached RMB 7.26B, surging 44.3% YoY. Management raised full-year growth guidance from 40% to ~45%. To meet booming demand, capacity expansion is underway, with peptide reactor volume expected to reach nearly 140,000 liters by year-end. With deep technical barriers and scale, TIDES has become the company's most explosive and certain growth driver.

High-Value "New Therapies" Surpass 35%, Injecting Long-Term Momentum

Beyond traditional small molecules, higher-value, more technically complex "new therapies" (ADC, RNA, multispecific antibodies) are reshaping the business mix. In 1H26, new therapies accounted for over 35% of WuXi Testing and WuXi Biology revenues, driving YoY growth of 31.5% and 11.2% respectively. New clients contributed over 20%, reflecting strong attraction of cutting-edge innovators. The deepening pipeline and structural upgrade of new therapies significantly enhance profitability and competitiveness, injecting long-term growth momentum.

26Q2 Backlog Up 25%+, CAPEX Expansion Boosts Visibility

WuXi AppTec demonstrated strong commercial visibility and execution. By end-Q2 2026, backlog from continuing operations reached RMB 66.43B, up 25.2% YoY. Based on robust reserves, management lifted full-year revenue growth guidance from 18–22% to 35–39%. At the same time, CAPEX guidance was raised from RMB 6.5–7.5B to RMB 7.5–8.5B, with early construction of a new Changzhou base and accelerated domestic and overseas capacity expansion. The combination of rising CAPEX and strong backlog provides exceptional visibility and assurance for future high growth.

Financials

	2024	2025	2026F	2027F	2028F
Revenue (CNY b)	39.2	45.5	60.0	72.6	85.3
Revenue YoY	-2.73	15.84	31.99	20.96	17.5
EPS (CNY)	3.2	6.7	7.6	9.1	10.6
EPS YoY	-10.99	107.41	13.52	19.31	16.9
RoE (%)	16.44	27.75	24.26	23.86	23.18

Estimate P/E

Order Backlog



Historical Volatility



Source: Bloomberg

US Equities Innovative Therapies and M&A Cycles Drive Biotech Growth

- July U.S. Core PCE rose 0.2% MoM, in line with expectations and above the prior −0.1%.
- July U.S. Durable Goods Orders increased 1.1% MoM, beating consensus 0.5% and prior 0.5%.
- Q2 U.S. GDP revised to 1.5% SAAR, matching forecasts but below the prior 2.1%.
- Aug U.S. Michigan Consumer Sentiment estimated at 51.7, above consensus 51.0 but down from 55.2.
- At the Jackson Hole Symposium, Fed Chair Kevin Warsh struck a hawkish tone, citing resilient growth and labor markets, inflation still above 2%, and the need to prioritize price stability over easing. He emphasized reducing reliance on forward guidance, adjusting policy based on real-time data and signals, and noted AI investment could lift productivity and potential growth. The stance suggests cautious near-term policy, with focus on upcoming inflation, jobs data, and the September FOMC.
- Biotech Sector Outlook 2026 shows improving fundamentals. Large pharma, pressured by patent expirations, is accelerating M&A, licensing, and external innovation, supporting capital inflows and valuations for smaller biotech firms. Breakthroughs in oncology, metabolic disease, ADC, RNA, gene editing, and radiopharmaceuticals continue, while AI enhances drug discovery and clinical efficiency. With financing conditions improving, IPOs and deal activity rising, and more innovative drugs nearing commercialization, the sector is poised for valuation recovery and earnings growth, with an overall positive investment outlook.

Biotechnology Market Size



Source: Bloomberg, Grand View Research

Twist Bioscience (TWST US)

Closing Price	US$141.38	Target Price	US$170

Twist Bioscience Corporation is a biotechnology company specializing in synthetic DNA applications. Its focus areas include biological detection, functional genomics, genome engineering, drug discovery, biodefense, and data storage. Twist Bioscience provides services to patients in the United States.

DNA Synthesis Scale Expansion, Margin Improvement

Twist benefited from rising demand in DNA synthesis, protein solutions, and NGS. FY26 Q3 revenue grew 23% YoY to USD 118.4M, marking 14 consecutive quarters of sequential growth. DNA synthesis and protein solutions revenue rose 39% YoY to USD 56.6M, with gross margin improving to 52.8%, reflecting higher capacity utilization and favorable product mix driving growth and operating leverage.

AI Drug Discovery and Personalized Medicine Boost DNA Demand

AI-driven drug discovery is accelerating the design of proteins, antibodies, and candidates, sharply increasing the number of biological sequences requiring synthesis and testing. Meanwhile, Moderna and Merck’s personalized mRNA cancer vaccines recently succeeded in Phase III trials, underscoring the broader shift toward genomics-driven and personalized therapies—where sequencing, variant identification, and rapid DNA synthesis are becoming critical research tools.

Mixed Q3 Results, Full-Year Guidance Raised

Q3 revenue reached USD 118.4M, up 23.2% YoY and beating consensus by USD 3.86M. GAAP net loss per share was USD −0.56, wider than expected by USD 0.08. For Q4, the company guides revenue of USD 123–124M and expects adjusted EBITDA breakeven. FY26 revenue is projected at USD 456–457M, above consensus USD 444.7M and prior guidance of USD 442–447M, with gross margin expected above 52%.

Valuation Consensus

Bloomberg’s 12-month average target price is USD 113, with a high of USD 120 and a low of USD 98.

1-Year Price

FY2026 Guidance



Financials

	2023	2024	2025	2026F	2027F
Revenue Growth(%)	20.4	27.7	20.3	21.1	19.3
EBITDA (%)	-65.8	-41.2	-25.6	-8.4	1.2
EPS (USD)	-3.46	-2.99	-1.95	-2.09	-1.37
Net Profit Margin(%)	-80.2	-55.4	-30.9	-26.3	-14.4

Source: Bloomberg; 2026/27F are market estimates

P/E & P/B

Source: Bloomberg, Company

Danaher Corporation (DHR US)

Closing Price US$216.07 **Target Price** US$240

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services, with operations spanning test and measurement, environmental, life sciences, dental, and industrial technologies.

Bioprocess Recovery and Masimo Expansion Drive Growth

Danaher's biotech segment is recovering, with FY26 revenue up 5.5% YoY to USD 6.3B. Bioprocess orders grew double digits, signaling improving demand despite project timing affecting reported revenue. The acquisition of Masimo adds advanced sensor technology and AI-enabled patient monitoring to diagnostics, strengthening recurring consumables and clinical diagnostics revenue alongside bioprocess expansion.

Biotech Innovation and Capacity Investment Support New Life Sciences Cycle

With biologics, cell and gene therapies, personalized medicine, and mRNA treatments expanding, biotech activity is rising. The first successful large-scale Phase III mRNA cancer vaccine trial provides validation for next-gen biologics. As therapies move from R&D into clinical development and commercialization, demand for Danaher's bioprocess equipment, consumables, analytical tools, and diagnostics is set to grow long-term.

Q2 FY26 Results Beat, Full-Year Outlook Raised

Q2 revenue reached USD 6.3B, up 5.5% YoY, with Non-GAAP EPS at USD 1.94, beating consensus by USD 0.99. Q3 revenue is guided to grow 2–3% YoY. FY26 full-year revenue is expected to rise 3–4%, with adjusted diluted EPS guidance raised to USD 8.45–8.60 (from USD 8.35–8.55).

Valuation Consensus

Bloomberg's 12-month average target price is USD 224.71, with a high of USD 310 and a low of USD 195.

1-Year Price



FY2026 Guidance Raised

	Q3E	Q4E	FY26E
Biotechnology	+MSD		**+MSD**
Life Sciences	~3.0-4.0%		**~3.0% to 4.0%**
Diagnostics	~Flat		**+Up slightly**
Danaher	~2.0-3.0%	+MSD	**~3.0% to 4.0%**
Danaher ex respiratory	~5.0%	+MSD	**+MSD**
Respiratory impact	*~ -2.5%*	*~Flat*	*-LSD*
Respiratory revenue*	~$325M	~$500M	**~$1.6B**
Respiratory revenue y/y	*~-35%*	*~Flat*	***-High-teens***

*Actuals round to nearest $50M

Financials

	2023	2024	2025	2026F	2027F
Revenue Growth(%)	-10.3	-0.1	2.9	6.7	7.9
EBITDA (%)	33.1	32.9	32.2	31.7	32.3
EPS (USD)	5.79	5.65	5.90	8.51	9.29
Net Profit Margin(%)	18.0	17.4	17.2	23.0	23.3

Source: Bloomberg; 2026/27F are market estimates

P/E & P/B

Source: Bloomberg, Company

TW Equities AI Demand Drives Taiwan Exports, Focus on Strong Q2 Results

Taiwan Stocks Break Short-Term Averages, Bullish Momentum Needs Volume

Taiwan equities opened lower but climbed steadily last week, with Tuesday and Wednesday showing gradual volume expansion and a breakout above short-term moving averages. Nvidia's strong earnings further boosted sentiment. With trading turnover expanding, short-term bullish momentum may continue, though sustained strength depends on daily turnover reaching the 20-day average. Near-term opportunities lie in optics, CCL, and AI servers. Stock selection should focus on Q2 earnings beats, July revenue growth, and strong H2 order visibility.

July Exports Beat Again, AI Server Demand Lifts Taiwan Tech

July export orders reached USD 97.94B, up 61.9% YoY, exceeding KGI's forecast of 54% and accelerating from June. AI-related demand remains stronger than expected, with ICT and electronics leading growth, while machinery and metals also benefit from semiconductor expansion and AI supply chain needs. U.S. hyperscalers continue to expand AI infrastructure and data center capex, with computing capacity still tight, supporting near-term demand for servers, semiconductors, and equipment. Many IT hardware firms posted Q2 2026 earnings above expectations, driven by AI server strength. Within industries, focus should be on system integrators (ODM, VGA, motherboard brands) showing the most significant profit upside in Q2.

TAIEX Index and Taiwan Electronics Sector Trends



Taiwan Export Orders Value and YoY Growth



Source: Bloomberg

Quanta Computer (2382 TT)

Quanta Computer is the world's largest notebook ODM. In the coming years, cloud services will be its key growth driver. The company is also expanding into servers, AIO PCs, wearables, and home AI products.

Q2 EPS Beats, AI Server Visibility Strengthens

Q2 2026 EPS reached NT$7.43, up 70% YoY and well above consensus, driven by strong revenue, margins, and non-operating gains. Cloud server revenue share remained above 80%, lifting overall revenue growth to 106% YoY. Management turned more optimistic on AI server growth, raising FY26 capex from NT$30B to NT$40B to expand facilities in Taiwan, the U.S., and Thailand, targeting global capacity doubling by 2026 and Taiwan capacity doubling by 2028.

Consignment Model Supports Stable 2H26 Margins

From Q3 2026 onward, some customers and projects will shift from buy-and-sell to consignment, where clients supply raw materials and Quanta provides manufacturing. This reduces working capital pressure and stabilizes margins in 2H26. Longer term, VR platform AI servers, ASIC, and neocloud outsourcing are expected to drive profitability, with AI server revenue continuing to fuel earnings growth into 2027.

Financials

	2023	2024	2025	2026F	2027F
EPS (NTD)	10.29	15.49	19.45	27.06	31.75
EPS Growth (%)	37.0	50.5	25.6	39.1	17.3
P/E Ratio	31.6	21.0	16.7	12.0	10.2
ROE (%)	22.3	29.2	32.2	41.1	44.2

Source: Company data, estimates of KGI analyst

Valuations



1-Year Price



As of 27 August 2026	1Wk	1M	3M	6M	YTD	1Y
Return (%)	1.99	3.57	6.89	14.41	22.61	23.98

Revenue Sources and Regions





Source: Bloomberg

Wistron (3231 TT)

Wistron Corporation manufactures and sells consumer electronics. The company produces notebooks, personal computers, smartphones, handheld devices, display products, and other related products.

AI Demand Strong, Positive 2H26 Outlook

Wistron reported Q2 2026 EPS of NT$4.72, up 54% QoQ and marking a recent quarterly high, driven by non-operating gains. Gross margin rose to 5.7% and operating margin to 3.7%, both improving YoY and QoQ, reflecting a stronger product mix and expanding server revenue scale. AI server components and systems are expected to continue growing in Q3, with new enterprise and CSP customers supporting stronger 2H26 performance versus 1H26.

Multiple AI Server Drivers to Boost 2027 Earnings

The 2027 outlook remains positive, with server shipments projected to rise from 18,000 racks to 20,000–25,000, driven by emerging CSP and cloud projects. Server revenue is expected to grow 57% YoY, with share rising to 85–90%. Expansion in Wiwynn ASIC and MI455 shipments, AMD components, Nvidia LPU substrates, and after-sales services shifting toward servers all add incremental growth drivers. We raised 2027 EPS forecast to NT$26.4, up 50% YoY, highlighting strong AI server demand underpinning medium- to long-term profitability.

Financials

	2023	2024	2025	2026F	2027F
EPS (NTD)	4.08	6.11	9.04	17.65	26.40
EPS Growth (%)	1.7	49.8	47.9	95.3	49.5
P/E Ratio	45.66	30.4	20.6	10.5	7.0
ROE (%)	11.4	14.7	17.7	28.2	34.8

Source: Company data, estimates of KGI analyst

Valuations



1-Year Price



As of 27 August 2026	1Wk	1M	3M	6M	YTD	1Y
Return (%)	-0.28	1.41	23.79	31.99	19.27	56.09

Revenue Sources and Regions



Source: Bloomberg

Mutual Funds/ ETFs

Integrating Diversified Strategies to Spread AI Holdings

► BlackRock Global Fund – US Basic Value Fund

- Established in January 1997, the fund is one of the few in the market focused on concentrated investments in large-cap U.S. value stocks.
- Through a disciplined value-investing strategy, it seeks to uncover undervalued opportunities among major U.S. companies.
- Adding value exposure in volatile markets can help balance risks from growth-oriented assets.
- Beyond technology, its top three sector allocations lean toward defensive industries such as healthcare and financials.

Product	BlackRock Global Fund – US Basic Value Fund	
Features	■ Focus on Value Strategy — The fund emphasizes companies with low valuations and intrinsic investment potential. ■ Diversified Allocation — No single industry accounts for more than 25% of the portfolio.	
AUM	USD 991 million	
3M/YTD Return	7.34% / 15.28%	
Top 5 Sector Allocation(%)	Information Technology Financials Healthcare Consumer Discretionary Industrials	17.00 15.74 14.92 12.50 10.32
Top 5 Country Allocation (%)	US	100
Top 5 Holdings (%)	AMAZON.COM INC MICROSOFT CORP APPLE INC CVS HEALTH CORP CITIGROUP INC	7.46 7.12 5.05 3.10 2.79

Source: Bloomberg, KGI

BlackRock Global Fund – US Basic Value Fund

Profile

The fund aims to enhance total return. At least 70% of its total assets are invested in equity securities of companies that are either registered in the United States or conduct the majority of their economic activities there.

Value Investing Strategy

The fund adopts a value investing approach, focusing on companies with low valuations and intrinsic investment potential. Managers aim to buy quality and stable stocks at appropriate price levels, making it suitable for investors seeking long-term stable returns.

Large-Cap Quality Stocks

It primarily invests in large-cap stocks across multiple industries, with at least 65% of the portfolio composed of securities covered by MSCI ESG Research. This enables investors to evaluate performance in environmental, social, and governance (ESG) aspects.

Diversified Portfolio

The portfolio is diversified, with no single industry accounting for more than 25% of total holdings. The top ten positions represent about 35.40% of the portfolio.

Inception	1997/1/8	**AUM**	USD 991 mn
Morningstar Category	US Large-Cap Value Stocks	**Fund Type**	Equities
Morningstar Rating	★★★	**3Y SD (Ann.)**	11.62%

Sectors



Top-5 Holdings (%)

AMAZON.COM INC	7.46
MICROSOFT CORP	7.12
APPLE INC	5.05
CVS HEALTH CORP	3.10
CITIGROUP INC	2.79

3Y NAV

As of 25 August 2026	**1M**	**3M**	**YTD**	**1Y**	**2Y**	**3Y**
Cumulative Return(%)	2.97	7.34	15.28	22.43	34.77	60.31
Ranking	3	2	2	1	2	1

Sources: BlackRock Asset Management Fund Monthly Report, Morningstar. Performance data as of August 25, 2026; monthly report as of July 31, 2026. Data share class: A2 USD.

Mutual Funds/ ETFs

Health Care Sector Resilient, Spending and Service Demand Growing

► BlackRock Global Fund - World Healthscience Fund

- The investment scope covers global health care, pharmaceuticals, medical technology, and biotechnology — industries with long-term inelastic demand.
- Managed by a top-tier team, the portfolio focuses on leading global health care companies including Eli Lilly, Johnson & Johnson, and AbbVie.

Product	BlackRock Global Fund - World Healthscience Fund	
Features	■ Aging Demand: Elderly care market long-term growth ■ Innovation + Defense: Biotech growth + defensive insurance & pharma	
AUM	USD 12.77 billion	
3M/YTD Return	13.11% / 9.05%	
Top 5 Sector Allocation(%)	Pharmaceuticals Biotechnology Life Sciences Tools & Services Health Care Providers & Services Health Care Equipment & Services	46.40 22.52 10.94 10.30 7.85
Top 5 Country Allocation (%)	US Switzerland UK Cash / Derivatives Denmark	74.61 10.72 5.80 1.99 1.64
Top 5 Holdings (%)	ELI LILLY JOHNSON & JOHNSON ABBVIE INC MERCK & CO INC UNITEDHEALTH GROUP INC	9.66 8.48 6.06 5.25 4.89

Source: Bloomberg, KGI

BlackRock Global Fund - World Healthscience Fund

Profile

The fund aims to enhance total return. It invests no less than 70% of total assets in equity securities of companies engaged globally in health care, pharmaceuticals, medical technology, and biotechnology supply and development.

■ Global Aging Trend Supports Long-Term Investment

With the world facing an aging population, demand for elderly health care services is set to grow steadily over time. Health care equities are well positioned as a long-term investment sector.

■ Leading U.S. Health Care Giants

The fund's core assets are heavily concentrated in the U.S. market, with over 70% allocation to global health care leaders such as Eli Lilly, Johnson & Johnson, and AbbVie.

■ Innovation and Defense Combined

This fund balances high-growth biotech (e.g., obesity and Alzheimer's drug innovation) with defensive allocations in health insurance services and traditional pharmaceutical leaders. The "offense + defense" strategy allows investors to capture explosive gains from new technologies while mitigating cyclical risks through stable health care demand.

Inception	2001/4/6	**AUM**	USD 12.77 bn
Morningstar Category	Health Care	**Fund Type**	Equities
Morningstar Rating	★★★★	**3Y SD (Ann.)**	12.58%

Sectors



Regional



Top-5 Holdings (%)

ELI LILLY	9.66
JOHNSON & JOHNSON	8.48
ABBVIE INC	6.06
MERCK & CO INC	5.25
UNITEDHEALTH GROUP INC	4.89

3Y NAV

As of 25 August 2026	1M	3M	YTD	1Y	2Y	3Y
Cumulative Return(%)	6.59	13.11	9.05	20.86	8.44	28.35
Ranking	2	2	2	2	2	2

Sources: BlackRock Asset Management Fund Monthly Report, Morningstar. Performance data as of August 25, 2026; monthly report as of July 31, 2026.Data share class: A2 USD.

Mutual Funds/ ETFs

Integrating Diversified Strategies to Spread AI Holdings

► Invesco S&P 500 Equal Weight ETF (RSP US)

- Aims to track the performance of the S&P 500 Equal Weight Index.
- Unlike the traditional market-cap weighted S&P 500, RSP assigns equal weight to all constituents and rebalances quarterly.
- Helps reduce concentration risk, limiting the outsized impact of a few large tech stocks, while providing more balanced exposure to U.S. large- and mid-cap equities.

Product	Invesco S&P 500 Equal Weight ETF (RSP US)	
Features	■ Equal Weight Protection: Avoids mega-cap dominance, stronger downside cushion in corrections ■ Quarterly Rebalance: Trims outperformers, adds underperformers, lowers volatility	
AUM	USD 96.96 billion	
Tracking Index	S&P 500 Equal Weight Index	
Currency	USD	
Exchange	NYSE	
Holdings	504	
Expense Ratio	0.20%	
3M/YTD Reutrn	7.38% / 16.89%	
Sectors (%)	Industrials Information Technology Financials Health Care Consumer Discretionary	16.77 15.18 15.10 11.98 9.45
Holdings (%)	Moderna Inc Zebra Technologies Corp Charles River Laboratories International Inc DoorDash Inc Expedia Group Inc	0.64 0.31 0.30 0.29 0.29

Source: Bloomberg

KGI

Invesco S&P 500 Equal Weight ETF (RSP US)

Profile

Tracks the S&P 500 Equal Weight Index, aiming to replicate the performance of its constituent stocks.

Equal Weight Investment Avoids Concentration
The index mirrors the S&P 500 holdings but applies equal weighting, reducing the risk of excessive concentration under cap-weighted allocation.

Stronger Downside Cushion in Volatile Markets
During the 2025 correction, RSP's maximum drawdown was 15.96% versus SPY's 18.76%, showing RSP's enhanced downside protection in market turbulence.

Buy Low, Sell High Rebalance
The ETF rebalances quarterly, trimming outperformers and adding underperformers — a built-in buy-low, sell-high mechanism that reduces overall volatility.

Inception	2003/4/24	**AUM**	USD 96.96 bn
ETF Category	Equities	**Holdings**	504
Expense Ratio	0.20%	**3Y SD (Ann.)**	13.15%

Sectors



Top-5 Holdings (%)

Moderna Inc	0.64
Zebra Technologies Corp	0.31
Charles River Laboratories International Inc	0.30
DoorDash Inc	0.29
Expedia Group Inc	0.29

Price Trend (Past 1 Year)

Volatility (Past 1 Year)



As of 26 August 2026	1M	3M	YTD	1Y	3Y	5Y
Cumulative Return(%)	4.00	7.38	16.89	19.98	16.55	9.27

Source: Bloomberg

Mutual Funds/ ETFs

Health Care Sector Resilient, Spending and Service Demand Growing

► State Street Health Care Select Sector SPDR ETF (XLV US)

- Aims to track the performance of the Health Care Select Sector Index, which covers industries including pharmaceuticals, medical equipment & supplies, health care providers, biotechnology, life sciences tools & services, and health care technology.
- Concentrates on large-cap growth stocks, with the top 10 holdings accounting for over 60% of the portfolio, including Eli Lilly, Johnson & Johnson, and AbbVie.

Product	State Street Health Care Select Sector SPDR ETF (XLV US)	
Features	■ Healthcare Leaders: Includes Eli Lilly, Johnson & Johnson, AbbVie; non-cyclical sector with low sensitivity to economic swings, offering defensive resilience. ■ Aging Demand Growth: Elderly care market shows long-term expansion driven by rigid demand.	
AUM	USD 41.75 billion	
Tracking Index	Health Care Select Sector Index	
Currency	USD	
Exchange	NYSE	
Holdings	60	
Expense Ratio	0.08%	
3M/YTD Reutrn	17.37% / 13.06%	
Sectors (%)	Pharmaceuticals Health Care Providers & Services Biotechnology Health Care Equipment & Supplies Life Sciences Tools & Services	38.07 18.78 18.52 15.46 8.70
Holdings (%)	Eli Lilly & Co Johnson & Johnson AbbVie Inc Merck & Co Inc UnitedHealth Group Inc	16.57 10.68 7.76 6.59 5.54

Source: Bloomberg

State Street Health Care Select Sector SPDR ETF (XLV US)

Profile

Tracks the Health Care Select Sector Index, aiming to replicate the performance of its constituent stocks.

■ Selected Health Care Leaders with Stable Earnings

This ETF includes major health care leaders such as Eli Lilly, Johnson & Johnson, and AbbVie, offering relatively steady profit performance.

■ Non-Cyclical Sector with Defensive Resilience

Health care is a non-cyclical industry, with operations less affected by economic fluctuations. During downturns, the sector typically demonstrates defensive strength.

■ Global Aging Trend Supports Long-Term Investment

With the world facing an aging population, demand for elderly health care services will continue to grow, making health care equities a suitable long-term investment sector.

Inception	1998/12/16	**AUM**	USD 41.75 bn
ETF Category	Equities	**Holdings**	60
Expense Ratio	0.08%	**3Y SD (Ann.)**	14.10%

Sectors



Top-5 Holdings (%)

Eli Lilly & Co	16.57
Johnson & Johnson	10.68
AbbVie Inc	7.76
Merck & Co Inc	6.59
UnitedHealth Group Inc	5.54

Price Trend (Past 1 Year)



Volatility (Past 1 Year)



As of 26 August 2026	**1M**	**3M**	**YTD**	**1Y**	**3Y**	**5Y**
Cumulative Return(%)	6.75	17.37	13.06	28.83	10.98	6.89

Source: Bloomberg

Bonds

Strong Government Backing, Solid Financials, with Allocation in Short- to Mid-Term Bonds

- **MTRC 4.375 04/01/30 (MTR Corporation) (USD)**
- **MTRC 4.886 01/29/31 (MTR Corporation) (AUD)**
  - MTR is Hong Kong's primary public transport operator and the city's sole metro and railway provider, holding about 50% of the franchised transport market. The Hong Kong government owns a 74.45% stake. Revenue streams include property development in Hong Kong, transport operations, station retail and advertising, property leasing and management, as well as Mainland China and international operations.
  - Looking ahead over the next decade, MTR plans to invest approximately HKD 100 billion in capital expenditures across five confirmed new railway projects, expected to drive long-term passenger growth and property development income. The company continues to launch new land tenders and property projects, providing potential earnings momentum.
  - Financially, the interest coverage ratio reached 11.25x in 2025, while net debt-to-equity declined from 31.6% in 2024 to 22.5% in 2025.
  - S&P and Moody's assigned issuer ratings of AA+ and Aa3, respectively, in line with Hong Kong SAR's sovereign ratings. This reflects MTR's critical role in Hong Kong's public transport system and the very high likelihood of special support from the Hong Kong government.

Bond	MTRC 4.375 04/01/30 (MTR Corporation) (USD)	MTRC 4.886 01/29/31 (MTR Corporation) (AUD)
ISIN	HK0001121083	AU3CB0330777
Features	S&P and Moody's assigned issuer ratings of AA+ and Aa3, respectively, in line with Hong Kong SAR's sovereign ratings. This reflects MTR's critical role in Hong Kong's public transport system and the very high likelihood of special support from the Hong Kong government.	
Maturity	2030/4/1	2031/1/29
Next Call Date	2030/3/1	2030/12/29
Coupon(%)	Fixed/4.375/Semi-annual	Fixed/4.886/Semi-annual
Currency	USD	AUD
Years to Maturity	3.59	4.42
Credit Rating (Moody's/ Fitch/S&P)	Aa3/-/AA+	Aa3/-/AA+
Seniority	Senior Unsecured	Senior Unsecured
YTM/YTC (%)	4.20/4.20	4.88/4.88

Source: Bloomberg

MTRC 4.375 04/01/30 (MTR Corporation) (USD)

MTR is Hong Kong's primary public transport operator and the city's sole metro and railway provider, holding about 50% of the franchised transport market. The Hong Kong government owns a 74.45% stake.

- Looking ahead over the next decade, MTR plans to invest approximately HKD 100 billion in capital expenditures across five confirmed new railway projects, expected to drive long-term passenger growth and property development income. The company continues to launch new land tenders and property projects, providing potential earnings momentum.
- Financially, the interest coverage ratio reached 11.25x in 2025, while net debt-to-equity declined from 31.6% in 2024 to 22.5% in 2025.
- S&P and Moody's assigned issuer ratings of AA+ and Aa3, respectively, in line with Hong Kong SAR's sovereign ratings. This reflects MTR's critical role in Hong Kong's public transport system and the very high likelihood of special support from the Hong Kong government.

Financials	2023	2024	2025
Return on Assets (%)	2.31	4.42	4.00
EBITDA Margin (%)	27.46	42.26	46.04
Interest Coverage Ratio	8.24	10.73	11.25

Overview

Name	MTRC 4.375 04/01/30	ISIN	HK0001121083
Maturity Date	2030/4/1	Remaining Maturity	3.59
Coupon(%)	Fixed/4.375/Semi-annual	YTM/YTC(%)	4.20/4.20
Currency	USD	Min. Subscription /Increment	200,000/1,000
Ratings (Moody's/Fitch/S&P)	Aa3/-/AA+	Seniority	Senior Unsecured

Price



Source: Bloomberg

MTRC 4.886 01/29/31 (MTR Corporation) (AUD)

MTR is Hong Kong's primary public transport operator and the city's sole metro and railway provider, holding about 50% of the franchised transport market. The Hong Kong government owns a 74.45% stake.

- Looking ahead over the next decade, MTR plans to invest approximately HKD 100 billion in capital expenditures across five confirmed new railway projects, expected to drive long-term passenger growth and property development income. The company continues to launch new land tenders and property projects, providing potential earnings momentum.
- Financially, the interest coverage ratio reached 11.25x in 2025, while net debt-to-equity declined from 31.6% in 2024 to 22.5% in 2025.
- S&P and Moody's assigned issuer ratings of AA+ and Aa3, respectively, in line with Hong Kong SAR's sovereign ratings. This reflects MTR's critical role in Hong Kong's public transport system and the very high likelihood of special support from the Hong Kong government.

Financials	2023	2024	2025
Return on Assets (%)	2.31	4.42	4.00
EBITDA Margin (%)	27.46	42.26	46.04
Interest Coverage Ratio	8.24	10.73	11.25

Overview

Name	MTRC 4.886 01/29/31	**ISIN**	AU3CB0330777
Maturity Date	2031/12/29	**Remaining Maturity**	4.42
Coupon(%)	Fixed/4.886/Semi-annual	**YTM/YTC(%)**	4.88/4.88
Currency	AUD	**Min. Subscription /Increment**	200,000/50,000
Ratings (Moody's/Fitch/S&P)	Aa3/-/AA+	**Seniority**	Senior Unsecured

Price



Source: Bloomberg

Appendix | Key Economic Data / Events

AUG 2026

24 Monday	25 Tuesday	26 Wednesday	27 Thursday	28 Friday
	• U.S. Aug Conference Board Consumer Confidence (Act:89.4 Est:90.2 Prev:90.2)	• U.S. Jul PCE YoY (Act:3.7% Est:3.6% Prev:3.7%) • U.S. Jul Core PCE YoY (Act:3.3% Est:3.3% Prev:3.3%) • U.S. Q2 GDP annualized QoQ (revised) (Act:1.5% Est:1.5% Prev:2.1%)	• U.S. Weekly Initial Jobless Claims (Act:203K Est:208k Prev:207k) • Jackson Hole Global Central Bank Symposium (08/27~08/29)	• U.S. Aug Univ. of Michigan Consumer Sentiment (final) (Est:51.0 Prev:55.2) • Japan Jul Unemployment Rate (Act:2.4% Est:2.5% Prev:2.5%)

SEP 2026

31 Monday	1 Tuesday	2 Wednesday	3 Thursday	4 Friday
• Japan Jul Retail Sales MoM (Est:1.6% Prev:-3.9%) • Japan Industrial Production MoM (prelim) (Est:-0.8% Prev:1.9%) • China Aug Manufacturing PMI (Est:49.6 Prev:49.2) • China Aug Non-Manufacturing PMI (Est:49.7 Prev:49.0)	• U.S. Aug S&P Global Manufacturing PMI (final) (Prev:53.9) • U.S. Aug ISM Manufacturing Index (Est:55.2 Prev:55.6) • U.S. Jul JOLTS Job Openings (Est:7,380k Prev:7,359k) • Japan Aug S&P Global Manufacturing PMI (final) (Prev:54.5) • Eurozone Aug S&P Global Manufacturing PMI (final) (Prev:51.9)	• U.S. Aug ADP Employment Change (Est:48k Prev:44k) • U.S. Jul Durable Goods Orders MoM (final) (Est:0.5% Prev:0.5%) • Earnings: PANW US, DELL US	• U.S. Weekly Initial Jobless Claims (Est:205k Prev:203k) • U.S. Aug S&P Global Services PMI (final) (Prev:54.6) • U.S. Aug ISM Services Index (Est:54.3 Prev:54.1) • Japan Aug S&P Global Services PMI (final) (Prev:51.2) • Eurozone Aug S&P Global Services PMI (final) (Prev:51.7) • Earnings: AVGO US	• U.S. Aug Nonfarm Payrolls (Est:55k Prev:-23k) • U.S. Aug Unemployment Rate (Est:4.1% Prev:4.1%) • Eurozone Jul Retail Sales MoM (Prev:-0.3%)

資料來源：Bloomberg

Key Earnings Releases

Date	Name	Revenue (F) (USD)	Actual Revenue (USD)	EPS (F) (USD)	Actual EPS (USD)	Exceed Expectation	
						Revenue	EPS
2026/8/27	Salesforce Inc. (CRM US)	11.32B	11.35B	3.28	5.90	V	V
2026/8/27	NVIDIA Corp. (NVDA US)	92.36B	96.22B	2.09	2.22	V	V
2026/8/27	CrowdStrike Holdings Inc. (CRWD US)	1.44B	1.47B	0.29	0.31	V	V

Source: Investing.com

Major Market / Asset YTD Performance

Equities & Bond Markets YTD Performance (%)



Currencies and Commodities Market YTD Performance (%)



Source: Bloomberg

Technical Analysis

60D MA

S&P 500 Index

- Current: 7,730
- 60D MA: 7,539

NASDAQ Index

- Current: 26,541
- 60D MA: 25,975

STOXX Europe 600 Index

- Current: 651
- 60D MA: 644

Nikkei 225 Index

- Current: 66,682
- 60D MA: 67,101

Shanghai Composite Index

- Current: 3,958
- 60D MA: 3,957

MSCI Emerging Markets Index

- Current: 1,722
- 60D MA: 1,688

Gold

- Current: 4,581
- 60D MA: 4,213

WTI Crude

- Current: 83.1
- 60D MA: 80.4



Market Monitor

U.S. CPI YoY (%)



U.S. 10-Year Treasury Yield (%)



U.S. Treasury Yield Spread (bps)



U.S. Treasury Yield Curve (%)



USD IG Credit Spread (%)



USD HY Credit Spread (%)



USD EM Credit Spread (%)



USD Asia Credit Spread (%)



Market Monitor

VIX Index



VIX Term Structure



U.S. Citi Economic Surprise Index*



U.S. Citi Inflation Surprise Index*



TED Spread (bps)



U.S. Dollar Index



EUR to USD



USD to JPY



Source: Bloomberg

Disclaimer and Important Notice

Hong Kong: The information contained in the document herein is confidential and is not intended for general public distribution or for use by any person or entity located or residing in any jurisdiction which restricts the distribution of such information by KGI Asia Limited ("KGI") or any affiliate of KGI. Re-distribution of the document herein and any part thereof by any means is strictly prohibited. Such information shall not be regarded as an offer, invitation, solicitation or recommendation to invest in or sell any securities or investment products to any person or entity in any jurisdiction. The above information (including but not limited to general financial and market information, news services, market analysis and product information) is for general information and reference purpose only and may not be reproduced or published (in whole or in part) for any purpose without the prior written consent of KGI Asia Ltd. Such information is not intended to provide investment advice and should not be relied upon in that regard. You are advised to exercise caution, and if you are in any doubt about such information, you should seek independent professional advice.

You are advised to exercise caution and undertake your own independent review, and you should seek independent professional advice before making any investment decision. You should carefully consider whether investment is suitable in light of your own risk tolerance, financial situation, investment experience, investment objectives, investment horizon and investment knowledge.

No representation or warranty is given, whether express or implied, on the accuracy, adequacy or completeness of information provided herein. In all cases, anyone proposing to rely on or use the information contained herein should independently verify and check the accuracy, completeness, reliability and suitability of the information. Simulations, past and projected performance may not necessarily be indicative of future results. Information including the figures stated herein may not necessarily have been independently verified, and such information should not be relied upon in making investment decisions. None of KGI, its affiliates or their respective directors, officers, employees and representatives will be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered or incurred by any person or entity due to any omission, error, inaccuracy, incompleteness or otherwise, or any reliance on such information. Furthermore, none of KGI, its affiliates or their respective directors, officers, employees and representatives shall be liable for the content of information provided by or quoted from third parties.

Complex Products refers to an investment product whose terms, features and risks are not reasonably likely to be understood by a retail investor because of its complex structure. Investors should exercise caution in relation to complex products. Investors may lose the entire amount or more than the invested amount. For complex products with offering documents or information not reviewed by the Hong Kong Securities and Futures Commission (SFC), investors should exercise caution regarding the offer. For complex products described as SFC-approved, such approval does not imply official endorsement, and SFC recognition does not equate to a recommendation or assurance of the product’s commercial viability or performance. Past performance data, if provided, is not indicative of future performance. Some complex products are only available to professional investors. Before making any investment decisions, investors should review the offering documents and other relevant information to understand the key nature, features, and risks of the complex products. Independent professional advice should be sought, and investors should have sufficient net assets to bear the potential risks and losses associated with the product. Members of the KGI group and their affiliates may provide services to any companies and affiliates of such companies mentioned herein. Members of the KGI group, their affiliates and their directors, officers, employees and representatives may from time to time have a position in any securities mentioned herein.

Bond investment is NOT equivalent to a time deposit. It is NOT protected under the Hong Kong Deposit Protection Scheme. Bondholders are exposed to a variety of risks, including but not limited to: (i) Credit risk - The issuer is responsible for payment of interest and repayment of principal of bonds. If the issuer defaults, the holder of bonds may not be able to receive interest and get back the principal. It should also be noted that credit ratings assigned by credit rating agencies do not guarantee the creditworthiness of the issuer; (ii) Liquidity risk - some bonds may not have active secondary markets and it would be difficult or impossible for investors to sell the bond before its maturity; (iii) Interest rate risk – When the interest rate rises, the price of a fixed rate bond will normally drop, and vice versa. If you want to sell your bond before it matures, you may get less than your purchase price. Do not invest in bond unless you fully understand and are willing to assume the risks associated with it. Please seek independent advice if you are unsure.

All investments involve risks. The prices of securities fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. Prices of securities and fund units may go up as well as down and past performance information presented is not indicative of future performance. Investors should read the relevant fund's offering documents (including the full text of the risk factors stated therein (in particular those associated with investments in emerging markets for funds investing in emerging markets)) in detail before making any investment decision. You are advised to exercise caution and undertake your own independent review, and you should seek independent professional advice before making any investment decision. You should carefully consider whether investment is suitable in light of your own risk tolerance, financial situation, investment experience, investment objectives, investment horizon and investment knowledge.

Singapore: This document is provided for general information and circulation only, and is not an offer or a solicitation to deal in any securities or to enter into any legal relations, nor an advice or a recommendation with respect to any financial products mentioned herein. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. You should ensure that you understand the risk(s) involved and should independently evaluate particular investments and consult an independent financial adviser before making any investment decisions. All information and opinions contained herein is based on certain assumptions, information and conditions available as at the date of this document and may be subject to change at any time without notice.